Home/Pipeline/CLS-014

CLS-014

Pancreatic Cancer

Pre-clinicalLead candidate

Key Facts

Indication

Pancreatic Cancer

Phase

Pre-clinical

Status

Lead candidate

Company

CLS Therapeutics

About CLS Therapeutics

CLS Therapeutics is translating the emerging biology of circulating nucleic acids into transformative gene therapies for cancer. Founded by scientists and biotech entrepreneurs, the company is advancing its lead program, CLS-014, a novel AAV vector encoding a hyperactive DNase I enzyme, to clean pathogenic cfDNA from patients' blood. With a team of experts in cfDNA research, gene therapy, and oncology, CLS is focused on treating gastrointestinal cancers and has engaged in strategic collaborations to advance its platform.

View full company profile

Therapeutic Areas

Oncology Gastrointestinal Cancer

Other Pancreatic Cancer Drugs

Drug	Company	Phase	Status
Ampligen® (rintatolimod)	AIM ImmunoTech	Early Access Program	Active - Approved in the Netherlands at Erasmus MC
HBM9027	Harbour BioMed	Phase 1	Active (Global)
Small-Molecule Therapeutic	AIkido Labs	Pre-clinical	Active
AHPBA IRE Registry	AngioDynamics	Post-Market Registry	Active
SIMBs + Immunotherapy	Advanced Microbubbles	Pre-clinical	Validated in preclinical studies
SOMA Platform	Coherence Neuro	Pre-clinical	Pipeline expansion launched in 2024
NP-G2-044	Novita Pharmaceuticals	Phase 2a	Orphan Drug Designated (Jan 2026)
Pritumumab (PTB)	Nascent Biotech	Phase II (Planned)	Exploratory
Pancreatic Cancer Test	Mosaique Diagnostic	Development	Active
Iontophoretic System	Continuity Biosciences	Pre-clinical	Active
Lixumistat (IM156)	ImmunoMet Therapeutics	Phase 1b	Active
Electron IORT	Intraop Medical	Approved	Active